> Products > Isavuconazole advance intermediat

China Isavuconazole advance intermediat Factory

We believe in: Innovation is our soul and spirit. Quality is our life. Shopper need is our God for Isavuconazole advance intermediat,CAS NO 241479-73-2,241479-73-2,Isavuconazole intermediate,1-(((2R,3S)-2-(2,5-difluorophenyl), our products have good reputation from the world as its most competive price and our most advantage of after-sale service to the clients。
Isavuconazole advance intermediat, Now, we are trying to enter new markets where we do not have a presence and developing the markets we have now the already penetrated. On account of superior quality and competitive price , we'll be the market leader, please don??￥t hesitate to contact us by phone or email, if you are interested in any of our goods.

Hot Products

Zaleplon
Product Name:Zaleplon
Molecular Formula:C17H15N5O
Molecular Weight;305.33
CAS Registry Number;151319-34-5
Methyl 5-nitroisophthalate
Product Name:Methyl 5-nitroisophthalate
Molecular Formula:C9H7NO6
Molecular Weight:225.15
CAS Registry Number:1955-46-0
Sotagliflozin
Product Name:Sotagliflozin
Molecular Formula:C21H25ClO5S
Molecular Weight;424.94
CAS Registry Number;1018899-04-1
7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
Product Name:7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
Molecular Formula:C16H14ClFN4O2
Molecular Weight:348.76
CAS Registry Number:2252403-82-8
2-Chloro-N-methylacetamide
Product Name:2-Chloro-N-methylacetamide
Molecular Formula:C3H6ClNO
Molecular Weight:107.54
CAS Registry Number:96-30-0
(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
Product Name:(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
Molecular Formula:C12H14ClN3O2
Molecular Weight:267.71
CAS Registry Number:1146629-75-5

Related Blog
Reviews

What is an Active Pharmaceutical Ingredient (API in Pharma)?
Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.
Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS
Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...
Development Trend of China's Pharmaceutical Intermediate Industry
The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.
Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry
Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.
Prostate Cancer and Darolutamide
Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).
FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC
On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

Isavuconazole advance intermediate

China Isavuconazole advance intermediat Factory

Related Products

Hot Products

Zaleplon

Methyl 5-nitroisophthalate

Sotagliflozin

7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

2-Chloro-N-methylacetamide

(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate

What is an Active Pharmaceutical Ingredient (API in Pharma)?

Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

Development Trend of China's Pharmaceutical Intermediate Industry

Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

Prostate Cancer and Darolutamide

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

Prudence 2022-07-01 21:50:05

Madge 2022-06-12 16:54:05

Riva 2024-03-14 20:48:28

Tina 2022-12-06 00:46:18

Ivy 2023-01-23 01:59:38

Arthur 2022-06-17 01:06:15

Related Search

Send Inquiry